Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
With
MUC Research GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants \>= 18 years of age.
Participants with documented HIV-1 infection.
Prescription of DTG + 3TC was issued independently from entering this study.
Participants with the ability to understand informed consent form and other relevant regulatory documents.
You may not be if
Any contraindication according to Tivicay or Lamivudine summaries of product characteristics (SmPCs).
Participants with VL \> 500 c/mL.
Any antiretroviral therapy for the treatment of HIV-1 in addition to DTG and 3TC or the DTG/3TC fixed dose combination (FDC).
Participants with hepatitis B virus (HBV)- coinfection.
Participants with current participation in the ongoing non-interventional study TRIUMPH (study number: 202033, NCT number: NCT02342769) or in any interventional clinical trial irrespective of indication.
Participants who had previously participated in clinical trials assessing DTG+ 3TC.
Clareo Health | Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
